Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-Blockers in Takotsubo Syndrome
2023-510213-25-01Phase 4Authorised
- Sponsor
- Fundación Casa del Corazón
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of carvedilol in Takotsubo cardiomyopathy (TCM) (2 arms), sponsored by Fundación Casa del Corazón. Primary endpoint: Recovery of left ventricular systolic function by WMSI at 7 days. Planned start Mar 2024; status: authorised.
02
Drugs
carvedilol
03
Conditions
Takotsubo cardiomyopathy (TCM)
Beyond the preview
Go deeper on 2023-510213-25-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510213-25-01.